Valbonne, France, March 7, 2017
TxCell SA (FR0010127662 - TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe inflammatory and autoimmune diseases as well as transplant rejection, will release its 2016 financial results on Thursday, March 9, 2017, post-market.
A conference call will be held on Friday, March 10 at 11:30am CET in English. The conference call will be followed by a Q&A session.
Investors and analysts may participate via the following number: +33 (0) 1 72 00 15 10 / PIN Code: 77520636#.
The presentation will be available on TxCell's website www.txcell.com in the Investors / Presentation and webcasts section.
Following the call, a replay will be available for 90 days. To listen to the replay, please dial:
- USA: +1 877 64 230 18
- United-Kingdom: +44(0) 2033679460
- France: +33(0)1 72 00 15 00
- PIN Code: 307441#.
TxCell SA published this content on 07 March 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 06 April 2017 09:44:15 UTC.
Original documenthttp://www.txcell.com/txcell-hold-conference-call-friday-march-10-2017-following-publication-2016-financial-results/
Public permalinkhttp://www.publicnow.com/view/A6803DDA2D8C99EA4F0713E1652BC8348CF6F800